Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)

Emphysema Clinical Trial

— LIBERATE  

Official title:

Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01796392
• Other study ID #: 600-0012
• Status: Completed
• Phase: N/A
• Start date: July 2013
• Est. completion date: April 2023

Study information

• Verified date: May 2023
• Source: Pulmonx Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to study an investigational medical device that is designed to produce lung volume reduction in diseased areas of the lungs in patients with severe emphysema.

Description:

The Pulmonx Zephyr Endobronchial Valve (EBV) is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The EBV are placed in the diseased region of the lung using bronchoscopy. Bronchoscopy is a way to access the lungs using a small tube with a camera on the end. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.

The LIBERATE Study is a clinical trial with two groups. Participants are assigned at random to the 'Treatment' group or to the 'Control' group. The 'Treatment' group will receive the Zephyr Endobronchial Valve (EBV) in combination with optimal medical therapy. The 'Control' group will receive optimal medical therapy alone. For every three participants in the study, two will go into the 'Treatment' group and one will go into the 'Control' group.

It is hypothesized that after placement of the EBV, lung function will be improved as compared to standard medical therapy alone.

Based on the 12-month follow up data from the LIBERATE Study, the Zephyr Endobronchial Valve System was approved by the FDA for the treatment of severe emphysema in June 2018. Following this PMA approval, and in agreement with the FDA, the ongoing long term follow-up (out to 5 years) of patients in the LIBERATE Study will now be conducted as a Post-approval study under the auspices of the "LIBERATE Extension Study". This is an administrative change with absolutely no change to the design or conduct of the study and, therefore has no material impact to the study participants or the study sites. All annual follow-up visits and evaluations are per the original LIBERATE Study protocol. Reporting to the FDA will be as the LIBERATE Extension Study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 190
• Est. completion date: April 2023
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Clinical and radiological evidence of emphysema

• Nonsmoking for 4 months prior to screening interview

• BMI less than 35 kg/m2

• Stable on current medication regimen

• Forced expiratory volume in one second (FEV1) between 15% and 45% of predicted value

• Residual Volume less than 175% predicted (determined by body plethysmography)

• Little or no collateral ventilation (CV-) as determined using the Chartis System

Exclusion Criteria:

• Had two or more hospitalizations over the last year for a COPD exacerbation

• Had two or more hospitalizations over the last year for pneumonia

• Had a prior lung transplant, lung volume reduction surgery, bullectomy or lobectomy

• Had a heart attack or congestive heart failure within the last 6 months

• Have heart arrhythmia

• Is alpha-1 antitrypsin deficient

Related Conditions & MeSH terms

• Emphysema
• Pulmonary Emphysema

Intervention

Device:
• EBV
This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.

Other:
• Optimal Medical Management
This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.

Locations

Country	Name	City	State
Brazil	Hospital de Clinicas Porto Alegre	Porto Alegre	RS
Brazil	INCOR - Hospital das Clinicas de Faculdade de Medicine da USP	São Paulo	SP
Netherlands	University Medical Center Groningen	Groningen
United Kingdom	Bristol Royal Infirmary	Bristol
United Kingdom	University Hospital Llandough and University Hospital of Wales	Cardiff
United Kingdom	Royal Brompton & Harefield NHS Foundation Trust	London
United States	The University of Alabama at Birmingham	Birmingham	Alabama
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Cleveland Clinic	Cleveland	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	Houston Methodist Hospital	Houston	Texas
United States	University of Southern California	Los Angeles	California
United States	University of Louisville Research Foundation	Louisville	Kentucky
United States	El Camino Hospital	Mountain View	California
United States	Orlando Health	Orlando	Florida
United States	Temple University Hospital	Philadelphia	Pennsylvania
United States	Arizona Pulmonary Specialists	Phoenix	Arizona
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	University of California at Davis Medical Center	Sacramento	California
United States	University of California, San Francisco	San Francisco	California
United States	Stanford University	Stanford	California
United States	Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
Pulmonx Corporation

Countries where clinical trial is conducted

United States,  Brazil,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Forced Expiratory Volume in 1-second (FEV1)	The percentage of study participants in the Zephyr Valve EBV (Endobronchial Valves) treatment arm meeting the clinically significant threshold of >15% improved forced expiratory volume in one second (FEV1), obtained immediately following bronchodilator therapy, as compared to the percentage in the control arm at 1 year post-procedure.	1 year
Secondary	FEV1 Post-bronchodilator Absolute Change	Difference between study arms in absolute change from baseline for post-bronchodilator FEV1 score at 1 year (value at 1 year minus value at baseline).	1 year
Secondary	St. George's Respiratory Questionnaire (SGRQ)	Difference between study arms in 'absolute change from baseline' for SGRQ score at 1 year (value at 1 year minus value at baseline).; The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. The questionnaire comprises of two parts: Part I: Symptoms (frequency & severity) Part II: Activities that cause or are limited by breathlessness; Impacts (social functioning, psychological disturbances resulting from airways disease); A Total score is calculated which summarizes the impact of the disease on overall health status. Scores range from 0 to 100, with higher scores indicating more limitations.	1 year
Secondary	6-minute Walk Distance	Difference between study arms in 'absolute and percentage change from baseline' for 6MWD at 1 year (value at 1 year minus value at baseline).	1 year